


REMARKSAmendments

By this amendment, Claim 1 has been amended by combining it with claim 2, so that the method of the invention only covers oligo- β -(1,3)-glucans of formula



in which $n=1$ to 7,

or a pharmaceutical acceptable salt thereof.

The remaining claims have been amended where necessary to conform with this amendment.

REJECTION UNDER 35 USC § 112

Claims 1-10 were rejected under 35 USC § 112 as non-enabled in that the Examiner argued that the specification did not enable one skilled in the art to use the invention commensurate with the scope of the prior claims. This rejection is respectfully traversed in that the claims are now directed to use of the specific compound of formula (I) as reflected in amended Claim 1, and this specific compound can be clearly and reliably be used in the therapeutical method of the claims by one of ordinary skill in the art.

REJECTIONS UNDER 35 USC § 102(b)

Claims 1, 5 and 6 as originally filed were rejected under 35 USC § 102(b) as being anticipated by YVIN et al.

Without addressing the merits of the rejection, this rejection is now respectfully traversed in that presently amended Claim 1 results from the combination of the subject matter of original claim 2, which was not rejected on the basis of prior art, into claim 1, and the Examiner's rejection should now be withdrawn as moot.

REJECTIONS UNDER 35 USC § 103(a)

Claims 1, 4-7, and 10 were rejected under 35 USC § 103(a) as being unpatentable over YVIN et al in view of HILLMAN et al. Furthermore, Claims 1 and 5-10 have been rejected as being unpatentable over YVIN et al in view of PENNEY et al.

Without addressing the merits of the rejection, this rejection is now respectfully traversed in that presently amended Claim 1 results from the combination of the subject matter of original claim 2, which was not rejected on the basis of prior art, into claim 1, and the Examiner's rejection should now be withdrawn as moot.

DOUBLE PATENTING REJECTION


Without addressing the merits of the rejection, this rejection is now respectfully traversed in that Applicants provide herewith a terminal disclaimer.

In view of the above, it is considered that the application is now in proper form for allowance.

Favorable consideration and prompt allowance of these claims are respectfully requested.

Respectfully submitted,
STITES & HARBISON, PLLC

April 21, 2006


B. Aaron Schulman
Registration No. 31877

1199 North Fairfax Street, Suite 900
Alexandria, Virginia 22314
703-739-4900